相关实验视频
Updated: Feb 28, 2026

12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
13.3K
抑制自身免疫:一种针对CD40-CD40L的新Fab片段阻止了B细胞的激活和分化
Kathrine Pedersen1, Kenneth Green1, Emil L Kristoffersen2
1Department of Biomedicine, Aarhus University, Aarhus, Denmark.
European journal of immunology
|February 26, 2026
概括
一个新的抗CD40L Fab片段,Fab20,有效地阻止B细胞激活和抗体产生. 这种治疗方法对自身免疫性疾病有希望,因为它可以避免与抗体疗法相关的Fc介导副作用.
科学领域:
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
- 治疗开发的治疗方法
背景情况:
- CD40-CD40L通路在自身免疫性疾病中至关重要.
- 以前的抗CD40L抗体试验由于Fc介导的副作用而面临挑战.
研究的目的:
- 开发和评估一种新的抗CD40L Fab片段,Fab20,作为自身免疫疾病的潜在治疗方法.
- 评估Fab20阻断B细胞激活和减轻Fc介导的不良影响的能力.
主要方法:
- 使用了免疫测试,冷电子显微镜和流细胞计.
- 在细胞培养中对人类B细胞的激活和分化进行了14天的分析.
- 描述了Fab20与CD40L的结合亲和力和结构相互作用.
主要成果:
- 对于CD40L结合,Fab20的解离常数为70nM.
- 结构分析显示,Fab20在硬质性上阻碍了CD40与CD40L的结合.
- Fab20有效地抑制了B细胞的激活,抑制了IgG的产生,并保持了B细胞的纯粹性.
结论:
- 通过向CD40-CD40L轴,Fab20代表了对自身免疫性疾病的有希望的治疗候选者.
- 与抗体疗法相比,Fab片段设计避免了Fc介导的效应,这表明它具有更好的安全性.
相关概念视频
B Cell Activation and Differentiation
17.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.4K
T Cell Activation and Clonal Selection
16.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
16.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658
Regulation of Hematopoietic Stem Cells
4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K

